JATT II Acquisition

This filing confirms the mechanical foundation of the trust ($60,000,000 deposited for the benefit of 6,000,000 public shareholders, initially anticipated to be $10.00 per Public Share per the notes), locks in the 24-month execution window, and details the precise capital stack and incentive structures governing the acquisition search. The disclosed compensation mechanics—straight-line monthly vesting over 24 months or full acceleration upon a business combination—tie sponsor and management retention directly to successful deal completion. Working capital loans remain available to fund transaction costs, with up to $1,500,000 potentially convertible into private placement shares at $10.00 per share, introducing defined dilution parameters. Public shareholders retain standard redemption rights calculable as of two business days prior to consummation, while the sponsor and underwriter have contractually waived claims against the trust account in a liquidation scenario. Because the entity is a blank check company with zero operating revenues and no selected target, all investor evaluation rests on the published execution deadline, trust protections, and subsequent prospecting disclosures rather than historical financial performance.

This filing establishes the initial trust value of $60,000,000 ($10.00 per public share), the 24-month deadline for a business combination (April 20, 2028), and the terms governing sponsor shares, lock-ups, and redemption rights. It provides the baseline for tracking future redemptions, extensions, and deal progress.

This filing establishes the full terms of the SPAC IPO, including trust per-share value ($10.00), redemption mechanics, deadline (April 2028), sponsor economics, and potential conflicts of interest. It is the baseline for all future redemptions, extensions, and deal progress. The indication of interest from AI Biotechnology for a potential $30 million PIPE is a notable feature that may affect deal financing and dilution.

Compressing the interval between SEC comment resolution and regulatory effectiveness dictates the sequencing of shareholder notices, which governs when redemption rights formally attach and how quickly transaction proceeds may be deployed. Management’s acceleration bid signals a preference for uninterrupted execution over procedural delay, implying continued sponsor alignment with the originally outlined business combination roadmap. Because the submission functions strictly as a timing mechanism under Section 461, it carries no independent financial or operational disclosures; investors must await subsequent proxy statements or merger agreements to verify concrete deal terms, valuation benchmarks, or contingent consideration structures.

This document provides the complete terms for JATT II's $60 million SPAC IPO. It confirms: a 24-month deadline from closing to complete a business combination (no automatic monthly extension); a $10.00 trust per share (with $0.30 deferred underwriting); a 20% per-shareholder cap on redemptions in a vote scenario; a commitment from sponsor to purchase 300k private placement shares at $10.00; and an indication of interest from AI Biotechnology (an Access Industries affiliate) for up to $30 million in a concurrent private placement at the time of the business combination. The filing also provides extensive biographical information on CEO Dr. Someit Sidhu (former JATT I / Zura Bio CEO) and the rest of the life-sciences-focused management team and board, outlining the sponsor's compensation and conflicts of interest.

Establishes the terms for potential investors, including trust value per share, redemption rights, sponsor promote structure, and the timeline for a business combination. Also discloses an indication of interest from AI Biotechnology for a $30 million PIPE at deal time, which is non-binding. The SPAC is led by a team with prior SPAC experience (JATT I/Zura Bio).

What changed: SEC Schedule 13G (beneficial ownership report). The filing identifies Atika Capital Management LLC and Brad Farber as the reporting persons disclosing beneficial ownership in JATT. The provided text contains no share counts, percentage thresholds, acquisition dates, or explicit statements characterizing the filing as passive or active. No data is presented regarding redemption mechanics, trust-per-share valuations, extension motions, target acquisition progression, or sponsor conduct. Why it matters: A Schedule 13G legally registers that one or more persons have crossed or maintained a greater-than-5% equity stake in a public company, establishing their formal voting rights and disclosure obligations. For a SPAC in the DEAL_ANNOUNCED phase approaching a 2028-04-20 deadline, identifying large non-sponsor blockholders helps map potential aggregate redemption exposure, proxy voting alignment on a business combination, or future governance influence, though this truncated excerpt lacks the numerical ownership data or strategic narrative required to quantify those dynamics.

What changed: A Power of Attorney exhibit filed to authorize designated corporate officers to prepare and submit ownership and control-person reporting documents to the Securities and Exchange Commission. Janus Henderson Group Ltd. appointed Kristin Mariani and Caroline Barotti as severally acting attorneys-in-fact on December 9, 2022, to execute Forms 13D, 13F, 13G, 13H, and amendments as required by U.S. and non-U.S. governmental authorities. Michelle Rosenberg, identified as General Counsel and Company Secretary, executed the instrument. The document contains no provisions altering redemption deadlines, trust account valuations, extension voting, merger progress, or sponsor conduct. No assertions regarding customers, revenues, market size, strategy, technology, partnerships, litigation, or personnel changes are attributed to any party. Why it matters: For investors tracking JATT’s transaction mechanics, this exhibit is purely administrative. It ensures Janus Henderson can timely satisfy SEC reporting obligations through designated employees, but it does not trigger shareholder redemption windows, modify trust distribution conditions, signal management shifts tied to the combination, or indicate changes in deal progress or sponsor alignment.

What changed: Quarterly Report (Form 10-Q) for the period ended June 30, 2026, filed August 12, 2026. This is the first 10-Q since the IPO (April 2026). It discloses the Business Combination Agreement signed on June 29, 2026 with Talawar Tx Inc., including a $225 million PIPE at $10/share, sponsor agreement to surrender 150,000 shares, and a minimum cash condition of $125 million. Trust account per share is $10.07, slightly above the $10.00 IPO price. The company has 24 months from IPO close (April 20, 2026) to complete the deal. No redemptions have occurred yet; the redemption mechanics are described. Why it matters: The filing confirms the target and deal structure, providing investors with key terms for evaluating the proposed business combination. The trust value per share ($10.07) offers a small cushion for redemptions. The PIPE at $10/share implies a $120 million pre-money valuation for the SPAC. The sponsor's forfeiture of 150,000 shares and other concessions indicate alignment. The 24-month deadline (April 2028) is distant, but the deal is already announced.

What changed: Form 4 insider ownership report. Per the June 30, 2026 filing, reporting person Sidhu Someit (identified in the submission as director, Chief Executive Officer, and 10% owner of JATT II Acquisition Corp.) disposed of 225,000 shares at $0 on June 6, 2026. The filing attests he holds 1,800,000 shares post-transaction. The document records no modifications to the $10.07 trust/share balance, the April 20, 2028 deadline, or the currently announced deal status. Why it matters: This filing does not trigger redemption clock resets, alter trust payout mechanics, or establish extension amendments. It exclusively documents executive equity movement following the merger announcement. Investors tracking sponsor conduct and insider alignment relative to the April 20, 2028 deadline should note the zero-price disposal as a disclosed baseline for current insider concentration; however, the filing contains no forward-looking statements, customer or revenue claims, partnership details, litigation references, or revised strategic targets. Trust parameters and deal progression remain static per the issuer's own representations.

What changed: Form 4 – insider ownership report documenting a beneficial ownership change for JATT II Acquisition Corp. The filing states that JATT Ventures II L.P., identified by the registrant as a 10% owner, disposed of 225,000 shares at $0 on 2026-06-06, leaving the reporting entity with 1,800,000 shares afterward. The document does not reference the $10.07 trust/share value, the 2028-04-20 redemption deadline, any extension provisions, or the advancement of the announced acquisition. It contains no executive commentary, customer metrics, revenue data, market analyses, technological disclosures, partnership announcements, litigation details, or personnel updates. Why it matters: A reported reduction in sponsor-affiliated holdings can alter the actual equity split between founding and public shareholders prior to the 2028-04-20 conversion window, though the $0 execution price points to a non-market mechanism such as an internal assignment, settlement, or reorganization rather than a liquidation event. Because the Form 4 supplies no explanatory narrative beyond the share-count delta, the economic intent remains opaque to investors monitoring sponsor alignment and potential dilution mechanics ahead of the deal close. The filing leaves the stated trust balance, redemption calendar, and deal status unchanged.

What changed: Form 8-K filed as a Rule 425 communication announcing the execution of a definitive Business Combination Agreement between SPAC JATT II Acquisition Corp and Talawar Tx Inc., a preclinical-stage biotech company developing bispecific antibodies for immunology/inflammatory diseases. Includes the full BCA, Sponsor Support Agreement, Stockholder Support Agreement, PIPE Subscription Agreements, Registration Rights and Lock-Up Agreement, and an investor presentation. New definitive business combination: JATT will merge with Talawar (via Merger Sub), with each JATT share converting to one share of the combined company (PubCo). Talawar pre-money equity valuation: $120M. PIPE: $225M at $10/share (22.5M shares). Trust account: ~$60M (as of signing, per JATT representation). Minimum cash condition: Available Cash at closing must be at least $125M. Sponsor forfeits 150,000 JATT shares for no consideration. Sponsor and certain company stockholders enter into a 180-day lock-up. Post-closing board: up to 7 directors – 1 designated by sponsor (Dr. Someit Sidhu) and up to 6 by Talawar. Officers designated by Talawar. Outside Date: January 31, 2027 (extendable if financial statements delayed). Why it matters: This is the definitive deal that will determine the future of JATT. The trust value is $10.07/share; the PIPE is at $10.00, providing a floor. Combined cash (~$285M assuming no redemptions) is expected to fund Talawar's lead candidate TALA-125 through Phase 2b proof-of-concept data readout in 2H 2028. The PIPE is oversubscribed with top-tier healthcare investors. Redemption risk is mitigated by a $125M minimum cash condition. Sponsor forfeiture of 150k shares reduces dilution. The investor presentation provides detailed preclinical data and development timeline. This is a high-quality biotech acquisition with strong investor backing.

What changed: Form 425 filing containing a prescribed business combination announcement and a republished Fierce Biotech interview article featuring comments from Talawar Tx Inc. Chief Executive Officer Marc Schegerin. On June 29, 2026, JATT II Acquisition Corp. and Talawar Tx Inc. executed a Business Combination Agreement that will make JATT an indirect wholly-owned subsidiary of Talawar. According to CEO Marc Schegerin in the republished interview, Talawar announced an oversubscribed $225 million concurrent private investment in public equity led by Access Biotechnology, with participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, and Farallon Capital Management. The parties state the combined company will receive $285 million total from JATT’s April IPO proceeds and the PIPE. JATT’s statutory business combination deadline remains April 20, 2028; the filing’s prospectus-style cautionary section reiterates the contractual risk that the transaction might not close by that date or that a sought extension could fail. No amendments to redemption procedures, trust accounting rules, sponsor equity warrants, or lock-up terms were disclosed in this communication. Why it matters: The PIPE term sheet and named anchor investors establish pre-vote institutional positioning ahead of the Form S-4 effectiveness, which triggers the formal registration/proxy sequence where JATT shareholders will be able to exercise redemption rights against the prevailing trust balance. The stated $285 million combined funding reservoir, paired with CEO Marc Schegerin’s clinical milestones (clinic entry in Q1 2027, interim phase 1 data by the end of 2027, and a phase 2b proof-of-concept readout penciled for H2 2028), outlines the milestone-driven burn schedule that will determine how much of the $10.07 per-share trust value survives closing versus being deployed to operations or dilutive financings. The filing’s explicit inclusion of SPAC-extinction and extension-failure risks reinforces standard termination protections without altering the redemption calendar or trust payout formula. Because the document primarily republishes a third-party interview rather than issuing original financial guidance, investors should treat all competitive landscape references (Sanofi, Regeneron, Eli Lilly, AbbVie), therapeutic mechanism claims, and strategic rationale as sourced commentary from the CEO and article author rather than audited corporate facts. For redemption trackers, this 425 communication finalizes the deal architecture and PIPE ledger, providing the necessary baseline to model trust preservation scenarios once the proxy statement is mailed and the extraordinary general meeting record date is set.

What changed: Form 8-K announcing a definitive business combination agreement between JATT II Acquisition Corp (SPAC) and Talawar Tx Inc. (target), including the merger agreement, sponsor support, PIPE financing, and related documents. JATT entered into a Business Combination Agreement with Talawar and Merger Sub on June 29, 2026. Key terms: (1) Each JATT share converts into one share of PubCo common stock; (2) A $225 million PIPE at $10.00 per share (22.5 million shares); (3) Sponsor (JATT Ventures II L.P.) agrees to vote in favor, waive redemption rights and anti-dilution, and forfeit 150,000 JATT shares for no consideration; (4) Minimum available cash condition of $125 million at closing; (5) Outside date for closing is January 31, 2027; (6) Combined company to be named Talawar Therapeutics and listed on Nasdaq under ticker ‘TLWR’; (7) Post-closing board: one sponsor director, up to six company directors; (8) Talawar’s lead program TALA-125 (anti-IL-13 x IL-18 bispecific for atopic dermatitis) expects CTA in YE 2026, Ph1 start 1Q27, Ph2b data 2H28; (9) Lock-up of 180 days for certain shares; (10) Registration rights filed within 30 days post-closing. Why it matters: This is the definitive agreement for the de-SPAC transaction. The trust per share is $10.07, but the PIPE price is $10.00, implying potential dilution. The $125 million minimum cash condition ensures sufficient operating capital. The valuation of Talawar at $120 million pre-money plus $225 million PIPE provides a pro forma equity value of ~$452 million. Sponsor share forfeiture reduces dilution. The lock-up restricts selling for 180 days. The investor presentation contains forward-looking clinical timelines and market projections for TALA-125. The transaction is subject to shareholder approval, SEC effectiveness, and Nasdaq listing.

What changed: A Form 425 communication reproducing a LinkedIn post announcing the execution of a business combination agreement between JATT II Acquisition Corp and Talawar Tx Inc. No alterations to redemption deadlines, trust accounting, extension mechanisms, or sponsor behavior are disclosed. The filing confirms the June 29, 2026 agreement date and establishes the immediate regulatory pathway: both parties intend to file a Form S-4 registration statement containing preliminary and definitive proxy materials and a prospectus, culminating in a mailout to JATT shareholders for an extraordinary general meeting vote. Why it matters: Although mechanically inert, the filing provides the first substantive public characterization of the target's business and associated risk profile. Both JATT and Talawar Tx Inc. state they anticipate benefits derived from preclinical and clinical development plans, therapeutic advantages of product candidates, and market positioning. Conversely, both entities attribute significant execution uncertainties to these projections, specifically highlighting the early stages of clinical development, reliance on third-party suppliers and manufacturers, outcomes of future collaboration agreements, and the ability to obtain regulatory approval for successful commercialization. Investors tracking the April 2028 deadline should prepare for detailed deal economics and voting conditions in the upcoming S-4.

What changed: Quarterly report (10-Q) for the period ended March 31, 2026, filed before the SPAC's IPO closed on April 20, 2026. It covers the pre-IPO formation stage, including deferred offering costs, sponsor promissory note, and no operations. As of March 31, 2026, the SPAC had not yet completed its IPO: it had no cash, a working capital deficit of $204,792, and a promissory note from sponsor of $106,141. On April 20, 2026, subsequent to quarter end, the IPO closed with 6,000,000 units at $10.00, raising $60 million for the trust account (initially $10.00 per share). No business combination target has been selected or discussed. Why it matters: This filing establishes the baseline trust value ($10.00 per share) and confirms the 24-month deadline (April 20, 2028) for completing a business combination. It details sponsor commitments, including the working capital loan facility and founder shares subject to forfeiture. No deal has been announced, so this is foundational for tracking future redemptions, extensions, and sponsor conduct.